<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Unaudited Consolidated Financial Statements of Genzyme Corporation and its
subsidiaries for the three months ended March 31, 1999 and is qualified in its
entirety by reference to such financial statements as included in the Form 10-Q
for Genzyme Corporation dated March 31, 1999.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS

                             
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               MAR-31-1999
<EXCHANGE-RATE>                                      1
<CASH>                                          80,591
<SECURITIES>                                   247,668
<RECEIVABLES>                                  177,780
<ALLOWANCES>                                    17,807
<INVENTORY>                                    110,567
<CURRENT-ASSETS>                               671,489
<PP&E>                                         536,314
<DEPRECIATION>                                 158,400
<TOTAL-ASSETS>                               1,721,053
<CURRENT-LIABILITIES>                          228,943
<BONDS>                                        284,415
<PREFERRED-MANDATORY>                            1,176
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   1,198,107
<TOTAL-LIABILITY-AND-EQUITY>                 1,721,053
<SALES>                                        163,702
<TOTAL-REVENUES>                               183,744
<CGS>                                           43,818
<TOTAL-COSTS>                                   55,906
<OTHER-EXPENSES>                                95,630
<LOSS-PROVISION>                                 2,356
<INTEREST-EXPENSE>                               5,498
<INCOME-PRETAX>                                 25,890
<INCOME-TAX>                                     9,833
<INCOME-CONTINUING>                             16,057
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    16,057
<EPS-BASIC>                                       0.53<F1><F2>
<EPS-DILUTED>                                     0.49<F1><F2>
<FN>
<F1>This financial data schedule has been restated to reflect the creation of
Genzyme Surgical Products Division on June 28, 1999. Genzyme Surgical Products
Division was created from programs and products that had previously been
included in the results of Genzyme General Division until the creation date of
June 28, 1999. All Genzyme General Division historical net income (loss) and
earnings (loss) per share amounts have been restated to reflect the creation of
this new division and Genzyme Surgical Products Division is now included as a
separate tracking stock of Genzyme Corporation.

<F2>Genzyme Corporation reports earnings per share based on its four tracking
stocks - Genzyme General Division Common Stock ("GENZ Stock"), Genzyme Surgical
Products Division Common Stock ("GZSP Stock"), Genzyme Molecular Oncology
Division Common Stock ("GZMO Stock") and Genzyme Tissue Repair Division Common
Stock ("GZTR Stock"). The earnings per share data presented on this schedule
reflects the earnings per share data for net income attributable to GENZ Stock.
For the three months ended March 31, 1999, net income attributable to Genzyme
General Division was $43,226 and net income per share of GENZ Stock on a basic
and diluted basis was $0.53 and $0.49, respectively. Net loss for Genzyme
Surgical Products Division for the three months ended March 31, 1999 was
$(10,745), and pro forma net loss per basic and diluted share of GZSP Stock was
$(0.73). Net loss for Genzyme Molecular Oncology Division for the three months
ended March 31, 1999 was $(7,060) or $(0.56) per basic and diluted share of
GZMO Stock. Net loss for Genzyme Tissue Repair Division for the three months
ended March 31, 1999 was $(9,616) or $(0.44) per basic and diluted share of
GZTR Stock.
</FN>